Mean blood pressure (BP) is widely considered to be of most importance in the etiology of vascular disease 1 ; hence, most guidelines for the management of arterial hypertension are based on mean BP. 2,3 However, evidence from observational studies and post-hoc analyses of clinical trials has shown that both short-term and long-term increases in BP variability (BPV) are associated with the development and progression of cardiac, vascular, and renal damage, and with an increased incidence of cardiovascular events and mortality independent of elevated mean BP. 4, 5 In patients with ischemic stroke, high systolic BPV is associated with the increased risk of cardiovascular and all-cause mortality independent of mean systolic BP (SBP), as well as other cardiovascular risk factors and comorbidities. 6 Although an increase in BPV might predict poor outcome after acute stroke, post-hoc analysis of 2 clinical trials, Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS) 7 and Continue Or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS), 8 showed no significant association between short-term systolic or diastolic BPV within 48 hours of stroke onset and early outcome (death or dependency at 2 weeks). 9 The aim of this study was to investigate the between mid-term BPV within 7 days of ischemic stroke onset and outcome.
patients with acute ischemic stroke were registered in the Stroke Registry database for optimal achieved BP. The study was approved by the ethic committee of the First People's Hospital of Lianyungang City, and written informed consent was obtained from each patient or his/her proxy.
Inclusion and exclusion criteria
Patients meeting all of the following criteria were eligible: acute ischemic stroke within 24 hours of onset; identified signs of focal neurological dysfunction; the National Institutes of Health Stroke Scale (NIHSS) scores ≥4 and the total scores ≥2 of the fifth motor arm and the sixth motor leg on NIHSS; ages between 40 and 75 years and SBP ≥140 mm Hg and/or diastolic BP (DBP) ≥90 mm Hg.
The patient would be excluded with any one of the following reasons: severe disturbance of consciousness identified by the level of consciousness on NIHSS score >1 (21 patients); the modified Rankin Scale (mRS) score >1 before stroke onset (0 patient); severe mental disorders and dementia (7 patients); serious systemic diseases and expectancy life span <90 days (24 patients); alanine transaminase or aspartate aminotransferase >2.0 upper limit of normal or severe liver disease (23 patients); estimated glomerular filtration rate <30 ml/min/1.73 m2 or sever kidney disease (13 patients) and inappropriate patients who would transfer to other communities in 1 year or could not finish 12-month follow-up due to poor compliance (25 patients). Finally, 873 patients were eligible for this study. Study flow diagram of patients' enrollment is shown in Figure 1 .
Measurement of BPV
The treatments for patients with acute ischemic stroke abided by 2013 American Heart Association/American Stroke Association (AHA/ASA) guidelines for the early management of patients with acute ischemic stroke, and antihypertensive strategies complied with 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines for the management of arterial hypertension. [10] [11] [12] Supine BP was measured by trained nurses with a standard mercury sphygmomanometer on the nonparalyzed arm on admission and every 4 hours from days 1 to 7 (the detailed time points were 1 am, 5 am, 9 am, 1 pm, 5 pm, and 9 pm). In the stroke unit, BP was measured using a noninvasive BP monitoring system (Philips SureSigns VM6 monitor; Royal Dutch Philips Electronics Ltd, Amsterdam, Netherlands) every 30 minutes within 6 hours, every 2 hours from 6 to 24 hours. In addition, BP was measured by trained nurses using a standard mercury sphygmomanometer every 4 hours in stroke unit. Twenty-four hours later, patients with stable mild stroke were transferred to general wards, in which trained nurses measured BP every 4 hours. However, severe stroke patients were treated in stroke unit continually, and measured BP every 2-4 hours by noninvasive BP monitoring system and every 4 hours by trained nurses, until they were in stable conditions and transferred to general ward. For every patient, BP was measured 3 times and averaged, and mean BP measurements were 26 (18-42) within 7 days. Finally, we used BP values every 4 hours measured by nurses to calculate the coefficient of variation (CV; 100 × SD/mean) of SBP and DBP within 7 days of stroke onset. 5 
Clinical assessment
Ischemic stroke was defined as the occurrence of stroke identified by radiographic diagnosis (computed tomography [CT] or magnetic resonance imaging [MRI] scanning) and clinical diagnosis. 13 The acute phase of ischemic stroke was defined as the time period within 7 days of symptom onset. 14 The infarct volume on CT/MRI (diffusion-weighted imaging/fluid attenuated inversion recovery [DWI/FLAIR]) images was calculated using Pullicino equation (net infarct volume = L × W × H/2; L, W, and H were referred as the length, width, and height of infarct lesion, respectively). 15 Thrombolytic therapy was defined as intravenous administration of recombinant tissue-type plasminogen activator (rt-PA) within 4.5 hours of symptom onset or catheterdirected thrombolysis using rt-PA within 12 hours of symptom onset.
Outcomes
All participants were followed up at 7 days, 14 days, 1 month, 3 months, 6 months, and 12 months by trained neurologists. Data on deaths, vascular events, BP, NIHSS score, and mRS score were obtained. In this study, clinical outcomes were assessed using the recovery situations of neurological function (good neurological recovery, neurological deterioration, and poor functional outcome) at 3 months and endpoint events (primary outcome and secondary outcome) within 12 months. The neurological severity (good neurological recovery and neurological deterioration) was assessed by the NIHSS score and the functional outcome was assessed by the mRS score. Good neurological recovery was defined as a decrease from baseline of 4 points or more on the NIHSS or 0 point, and neurological deterioration was defined as an Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CIV, cerebral infarct volume; CKD, chronic kidney disease; CV, coefficient of variation; DBP, diastolic blood pressure; HR, heart rates; mRS, modified Rankin scale; NIHSS, National Institute of Health stroke scale; PCI, posterior circulation infarcts; SBP, systolic blood pressure; SCS, significant carotid stenosis; TT, thrombolytic therapy; TIA, transient ischemic attack.
increase from baseline of 1 point or more on the NIHSS. 16 Poor functional outcome was defined as disability (a score of 2 to 5 on mRS), recurrent stroke, and all-cause mortality at 3 months. The primary outcome was symptomatic recurrent stroke within 12 months. The secondary outcomes included recurrent stroke, all-cause mortality, and the composite of cardiovascular events (cardiovascular mortality, nonfatal stroke [ischemic and hemorrhagic], and nonfatal myocardial infarction) within 12 months. Recurrent stroke included ischemic stroke (fatal and nonfatal) and hemorrhagic stroke (fatal and nonfatal). Cardiovascular mortality was defines as death due to lethal cardiac arrhythmias, congestive heart failure, myocardial infarction, sudden cardiac death, and other known vascular causes. Rehabilitation was defined as NIHSS score <2. 17
Statistical analysis
Continuous variables were presented as mean ± SD and were compared using the Student t test. Categorical variables are expressed as frequency and percentage and were compared using χ 2 test. To evaluate the association between midterm BPV and outcomes, patients were divided into quintiles (Q1-Q5) according to the CV of SBP and DBP within 7 days of stroke onset. Q1 was used as the reference. Some variables were selected to be included in the logistic regression models. Model 1 was adjusted for age and gender; model 2 was adjusted for age and gender plus categorical variables, including current smoker, hypertension, diabetes mellitus, hyperlipidemia, history of transient ischemic attack, significant carotid atherosclerosis, coronary artery disease, congestive heart failure, chronic kidney disease, posterior circulation infarction, and thrombolytic therapy; in model 3, more continuous variables were included on the basis of model 2, including SBP at admission, DBP at admission, mRS score, NIHSS score, cerebral infarct volume, and heart rates. The results of the recovery situations of neurological function at 3 months were present as odds ratios (ORs) and 95% confidence intervals (CIs). Kaplan-Meier survival analysis with a nonparametric log-rank test was used to compare the cumulative proportion of primary and secondary outcomes within 12 months in relation to different CV quintiles. Hazard ratios (HRs) and their 95% CIs were calculated in relation to the lowest quintile of CV as referent. P <0.05 was considered statistically significant. Statistical analysis was performed with SPSS.v19.0.1 software packages.
RESULTS

Clinical characteristics
Total 873 patients with acute ischemic stroke were included. All of them were confirmed by CT/MRI scans within 24 hours after admission. Simultaneously, infarct volumes were measured by CT scans in 93 (12.94%) patients or by MRI (DWI/FLAIR) scans in 780 (87.06%) patients. Total 48 patients were treated with thrombolysis. Among the 48 patients, 41 were treated with intravenous rt-PA and 7 received catheter-directed thrombolysis (rt-PA). At 12 months, 21 patients lost to follow-up. Among 852 Table 2 . CV within 7 days of onset and primary and secondary outcomes within 12 months The primary outcome was symptomatic recurrent stroke within 12 months. The secondary outcomes included recurrent stroke, all-cause mortality, and the composite of cardiovascular events (cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction) within 12 months. Abbreviations: CV, coefficient of variation; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
Clinical outcomes
During 3 months' follow-up, 33 patients died and 5 patients lost (Figure 1 ). Among 873 patients with ischemic stroke, 125 developed recurrent stroke and 212 developed cardiovascular events (cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction) during 12 months' follow-up (Table 2 ). In 212 patients with the occurrence of cardiovascular events, 65 were nonfatal myocardial infarction. Within 12 months, 50 patients died and 22 of deaths were due to cardiovascular causes ( Table 2 ).
BPV and recovery of neurological function
In multivariate logistic regression models, associations between mid-term BPV (within 7 days of stroke onset) and the recovery situations of neurological function at 3 months were determined. In model 1 adjusted for age and gender, CV of SBP in the 5th quintile was negatively associated with good neurological recovery (OR = 0.38; 95% CI: 0.29-0.48; P = 0.002), and it was positively associated with neurological deterioration (OR = 2.16; 95% CI: 1.62-2.71; P = 0.005), compared with that in the 1st quintile (Table 3A and B). In model 2 (based on model 1 plus categorical variables) and model 3 (based on model 2 plus continuous variables), the associations between CV of SBP and neurological severity still remained significant (Table 3A and B) . Similarly, CV of DBP was also associated with neurological severity in the 3 models (Table 3A and B) . Moreover, compared with those in the 1st quintile, both CV of SBP and CV of DBP in the 5th quintile were significantly associated with poor functional outcome in model 3 after adjustment for more conventional risk factors (systolic BPV: OR = 2.02, 95% CI: 1.52-2.53, P = 0.001; diastolic BPV: OR = 1.51, 95% CI: 1.14-1.89, P = 0.046) (Table 3C ).
BPV and primary and secondary outcomes
Importantly, higher CV of SBP was significantly correlated with the increased risk of recurrent stroke (HR: 2.32; 95% CI: 1.29-4.18; P = 0.005) and composite cardiovascular events (HR: 2.22; 95% CI: 1.41-3.48; P = 0.001) during 12 months' follow-up (Figure 2a and b) . However, there were no significant differences in the risk of all-cause mortality (P = 0.084) or cardiovascular mortality (P = 0.344) among patients with different quintiles of CV of SBP within 12 months (Table 4) Model 1 was adjusted for age and gender; model 2 was adjusted for age and gender plus categorical variables, including current smoker, hypertension, diabetes mellitus, hyperlipidemia, history of transient ischemic attack or stroke, significant carotid atherosclerosis, coronary artery disease, congestive heart failure, chronic kidney disease, posterior circulation infarction, and thrombolytic therapy; in model 3, more continuous variables were included on the basis of model 2, including mean SBP at admission, mean DBP at admission, mRS score, NIHSS score, cerebral infarct volume, and heart rates. Abbreviations: CI, confidence interval; CV, coefficient of variation; DBP, diastolic blood pressure; OR, odd ratio; SBP, systolic blood pressure. Table 3 . Continued during 12 months' follow-up (Figure 2c and d) . But higher CV of DBP still had no associations with the increased risk of all-cause mortality (P = 0.193) or cardiovascular mortality (P = 0.345) within 12 months (Table 4) .
DISCUSSION
The results of our study demonstrated that high midterm BPV (within 7 days of onset) was associated with an increased risk of recurrent stroke and composite cardiovascular events within 12 months. Moreover, elevated mid-term BPV was positively correlated with neurological deterioration and poor functional outcome, and negatively with good neurological recovery at 3 months. Such associations were independent of age and gender, as well as other cardiovascular risk factors, mRS score, NIHSS score, and cerebral infarct volume.
BPV is a complex phenomenon that includes short-term fluctuations occurring within a 24-hour period as well as BP changes over more-prolonged periods of time. 5, 18 These variations of BP are thought to be the result of complex interactions between extrinsic environmental and behavioral factors and intrinsic cardiovascular regulatory mechanisms (neural central, neural reflex, and humoral influences) that are not yet completely understood. 5 Furthermore, it is uncertain whether lowering BP with drugs in acute stroke might have favorable effects on outcome. The ACCESS Study 19 : evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors demonstrated that a 7-day course of candesartan after an acute ischemic stroke significantly improves cardiovascular morbidity and mortality, whereas the angiotensinreceptor blocker candesartan for treatment of acute stroke (SCAST) trial 20 showed that careful BP-lowering treatment with candesartan is not beneficial in patients with acute stroke and raised BP. However, high short-term BPV is a predictor of target organ damage and of future cardiovascular events, 21, 22 and high long-term BPV is predictive of cardiovascular events and all-cause mortality. [23] [24] [25] In these analyses, therefore, the predictive value of BPV might be even greater than that of average BP during treatment.
A post-hoc analysis of the Tinzaparin in Acute Ischemic Stroke Trial (TAIST) showed that systolic BPV within the first 48 hours after ischemic stroke is significantly associated with death or early neurological deterioration within 10 days. 26 But another post-hoc analysis of 2 trials (CHHIPS and COSSACS) showed that short-term BPV is not a useful predictor of early (2 weeks) outcome after acute stroke. 9 The discordance with previous studies indicating short-term and long-term prognostic value may result from different methodology. 9 Moreover, visit-to-visit systolic BPV predicts long-term (a mean follow-up of 76 ± 18 months) all-cause and cardiovascular mortality in patients with ischemic stroke without atrial fibrillation. 6 In addition, it is a strong predictor of subsequent stroke in patients with previous transient ischemic attack. 27 Our data revealed that mid-term systolic and diastolic BPV (within 7 days of onset) was associated with the increased risk of recurrent stroke and composite cardiovascular events in patients with acute ischemic stroke during a follow-up of 12 months. But there were no associations between mid-term systolic and diastolic BPV and all-cause and cardiovascular mortality within 12 months. Some potential mechanisms for long-term BPV, particularly increased arterial stiffness, have been postulated in previous studies. 28 It has been shown that day-to-day BPV identified by home BP monitoring is associated with increased severity of cardiac and vascular, and with an increased risk of fatal and nonfatal cardiovascular events. 23, 29, 30 The results from our study also demonstrated that mid-term BPV was correlated with the increased risk of long-term recurrent stroke and cardiovascular events, which were consistent with these studies.
After acute ischemic stroke, it is important to assess neurological improvements at 3 months. There is an evident consensus that functional outcome measured by mRS score is appropriate for trials intending to demonstrate sustained benefit of acute treatment in stroke, and the NIHSS score is useful for serial monitoring of patients after stroke to detect neurological worsening. 31 Previous study only demonstrated a high post-stroke BP is significantly associated with unfavorable clinical outcomes at 3 months in patients with acute ischemic stroke. 16 Recently, one study showed that day-to-day SBP variability during the 7 days of onset in acute ischemic stroke is associated with poor functional outcomes at 12 months. 32 In the present study, we assessed the associations between systolic and diastolic BPV and the recovery situations of neurological function including good neurological recovery, neurological deterioration, and poor functional outcome. To be more important, our study indicated that the multivariate-adjusted ORs (95% CI) in the highest quintile of systolic BPV (vs. the lowest quintile as a reference) were 0.39 (0.29-0.49) for a good neurological recovery, 2.21 (1.65-2.76) for neurological deterioration, and 2.68 (2.01-3.35) for a poor functional outcome. Similar associations were observed when diastolic BPV was applied. Therefore, in patients with acute ischemic stroke midterm BPV (within 7 days of onset) was also associated with neurological improvements at 3 months.
Some limitations of the present study need to be addressed. First, selection bias might have arisen because we excluded patients with massive ischemic stroke (NIHSS score > 24) or deep coma. Second, the correlation between cerebral lesion site and BPV was not investigated. A previous study demonstrated that patients with vascular compression on the rostral ventrolateral medulla had greater variability in BP during the acute ischemic stroke phase, which may be related to poorer prognosis. 33 However, in the present study, the influence of ischemic location on BPV was not considered, so the association between BPV and prognosis may be limited. Third, some measures of arterial stiffness were not performed. Though we tried to get ankle brachial index of these patients, we could not immediately measure that after admission because it would take long time to complete this measurement. Furthermore, the results of different measurements in different days were not consistent due to treatment of hypertension. Lastly, the sample size was smaller than that in our original study design. Based on the actual situation, we analyzed the correlation between BPV and prognosis. It was a real clinical practice, in which strict inclusion criteria were used, data were reasonably analyzed, and conclusion was carefully concluded. It could deliver useful suggestion for the management of ischemic stroke patients. In conclusions, in acute ischemic stroke patients, midterm BPV was associated with the recovery situations of neurological function at 3 months and primary outcome (recurrent stroke) within 12 months, as well as composite cardiovascular events within 12 months.
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